Compared to postoperative chemotherapy combined with radiotherapy, preoperative chemotherapy combined with radiotherapy shows higher sphincter preservation rate and lower local recurrence rate in locally advanced rectal cancer. The purpose of this study is to evaluate the response and prognosis of intraarterial chemoembolization and intravenous infusion chemotherapy in patients with rectal T3-T4 and/or N+ rectal cancer before operation.

Inclusion Criteria:

• Histologic or cytologic diagnosis of rectal cancer, Stage IV.
• Males or females between 18 Years to 75 Years.
• No prior cisplatin-based chemotherapy or radiotherapy.
• Performance status of 0～2 on the ECOG criteria.
• Adequate hematologic (Leukocyte count >= 4,000/uL, neutrophil count >= 1,500/uL, hemoglobin >= 10 g/dL, platelets >= 100,000/uL), hepatic (AST & ALT =< upper normal limit(UNL)x1.5, bilirubin level =< UNLx1.5), and renal (creatinine =< UNL x1.5 or creatinine clearance rate ≥60 ml/min) function.
• Patient can take oral medicine
• Patient compliance that allow adequate follow-up. Informed consent from patient or patient's relative.

Exclusion Criteria:

• Patient with allergic to S-1 or ingredient of Oxaliplatin
• Patient with Peripheral neuropathy
• Diagnosed fibrosis of lung;pulmonary fibrosis or interstitial pneumonia within 28 days.
• Medically uncontrolled serious heart, renal failure, liver failure, hemorrhagic peptic ulcer, paralysis of intestine , ileus, poor controlled diabetes.
• Enrollment in other study.
• Pregnant or breast-feeding.
• Seriously psyche or intelligence problem.
• Inability to comply with protocol or study procedures.